Therapeutic effect of a novel long-actingGLP-1/GIP/Glucagon triple agonist (HM15211) in CDHFD-induced NASH and fibrosis mice

被引：0
|
作者：
Choi, J. [1 ]
Jo, H. [1 ]
Kim, J. [1 ]
Kwon, H. [1 ]
Lee, J. [1 ]
Bae, S. [1 ]
Kim, D. [1 ]
Lee, S. [1 ]
Choi, I. [1 ]
机构：
[1] Hanmi Pharm Co Ltd, Hwaseong Si, Gyeonggi Do, South Korea
来源：
DIABETOLOGIA | 2020年 / 63卷 / SUPPL 1期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
127
引用
收藏
页码：S64 / S64
页数：1
相关论文
共 50 条
  • [21] ANTI -FIBROTIC EFFECT OF A NOVEL LONG-ACTING GLUCAGON/GIP/GLP-1 TRIPLE AGONIST (HM15211) IN BDL-INDUCED MOUSE MODEL OF LIVER FIBROSIS
    Kim, Jung Kuk
    Jo, Hyo Sang
    Lee, Seon Myeong
    Lee, Jong Suk
    Kwon, Hyunjoo
    Lee, Jong Soo
    Bae, Sung Min
    Lee, Sang Hyun
    Choi, In Young
    HEPATOLOGY, 2020, 72 : 1009 - 1010
  • [22] STUDY ON MULTI-TARGET ENGAGEMENT EFFECT OF A NOVEL LONG-ACTING GLUCAGON/GIP/GLP-1 TRIPLE AGONIST, HM15211, IN ANIMAL MODEL OF NASH
    Lee, Jong Suk
    Kim, Jung Kuk
    Lee, Seon Myeong
    Choi, Jaehyuk
    Kwon, Hyunjoo
    Park, Eun Jin
    Lee, Jong Soo
    Kim, Dae Jin
    Lee, Sang Hyun
    Choi, In Young
    HEPATOLOGY, 2021, 74 : 1088A - 1089A
  • [23] Neuroprotective effects of HM15211, a novel long-acting GLP-1/GIP/glucagon triple agonist in the neurodegenerative disease models
    Kim, J.
    Lee, S.
    Lee, S. -H.
    Jung, S.
    Kim, Y.
    Choi, I.
    Kim, S.
    DIABETOLOGIA, 2018, 61 : S84 - S85
  • [24] ANTI-FIBROTIC POTENTIAL OF A NOVEL LONG-ACTING GLUCAGON/GIP/GLP-1 TRIPLE AGONIST, HM15211, IN PRECLINICAL MODELS OF FIBROSIS
    Kim, Jung Kuk
    Lee, Jong Suk
    Lee, Seon Myeong
    Choi, Jaehyuk
    Kwon, Hyunjoo
    Park, Eun Jin
    Bae, Sung Min
    Kim, Dae Jin
    Kim, Young Hoon
    Choi, In Young
    HEPATOLOGY, 2021, 74 : 1055A - 1056A
  • [25] Antifibrotic Potential of a Novel Long-Acting Glucagon/GIP/GLP-1 Triple Agonist (HM15211) in Preclinical Models of IPF
    Kim, Jeong A.
    Lee, Jong Suk
    Kim, Jung Kuk
    Ban, Young-Hwan
    Lee, Jongsoo
    Bae, Sungmin
    Kim, Daejin
    Lee, Sang Hyun
    Choi, In Young
    DIABETES, 2022, 71
  • [26] Neuroprotective effects of HM15211, a novel long-acting GLP-1/GIP/Glucagon triple agonist in the neurodegenerative disease models
    Kim, W.
    Kim, J.
    Lee, S. -H.
    Bae, S.
    Choi, I.
    Kim, Y.
    DIABETOLOGIA, 2019, 62 : S292 - S292
  • [27] Neuroprotective Effects of HM15211, a Novel Long-Acting GLP-1/GIP/Glucagon Triple Agonist in the Neurodegenerative Disease Models
    Kim, Jeong A.
    Lee, Sangdon
    Lee, Sang Hyun
    Jung, Sung Youb
    Kim, Young Hoon
    Choi, In Young
    Kim, Sun Jin
    DIABETES, 2018, 67
  • [28] Potential effect of a novel long-acting Glucagon/GIP/GLP-1 triple agonist, HM15211, in preclinical model of cholestatic liver disease
    Kim, Jung Kuk
    Lee, Jong Suk
    Kim, Yohan
    Choi, Jae Hyuk
    Kwon, Hyunjoo
    Park, Eun Jin
    Lee, Jong Soo
    Bae, Sung Min
    Lee, Sang Hyun
    Choi, In Young
    JOURNAL OF HEPATOLOGY, 2021, 75 : S417 - S417
  • [29] Improvement of liver fibrosis by a novel long acting Glucagon/GLP-1/GIP triple agonist, efocipegtrutide (HM15211) in carbon tetrachloride-induced mouse model of liver injury and fibrosis
    Lee, Jong Suk
    Kim, Yohan
    Kim, Jung Kuk
    Kwon, Hyunjoo
    Park, Eun Jin
    Kim, Jeong A.
    Park, Sang Hyun
    Bae, Sung Min
    Lee, Sang Hyun
    Choi, In Young
    JOURNAL OF HEPATOLOGY, 2023, 78 : S779 - S780
  • [30] HM15211, a Novel Long-Acting GLP-1/GIP/Glucagon Triple Agonist, Exhibits Anti-inflammatory and Fibrotic Effects in AMLN/TAA-Induced Liver Inflammation and Fibrosis Mice
    Kim, Jung Kuk
    Lee, Jong Suk
    Park, Eunjin
    Lee, Jongsoo
    Bae, Sungmin
    Kim, Daejin
    Choi, In Young
    DIABETES, 2020, 69
12345